GSK's commitment
This GlaxoSmithKline global community outreach program is dedicated to giving thousands of people in Africa and the developing world hope after HIV—through research and development of new HIV medicines and vaccines, preferential pricing for antiretrovirals, community investments, and innovative partnerships. The following is a brief summary of some of the initiatives undertaken by GlaxoSmithKline:
Research & development of antiretrovirals
- Conducted first human trials of HIV vaccine
- Undertaking R&D for the prevention and treatment of HIV/AIDS, tuberculosis, and malaria
- Have supported more than 25 ongoing and past clinical trials in developing countries, including 19 in Africa
- Nurturing the broadest discovery and development pipeline of antiretrovirals, anti-malarials, and vaccines
Community investment
- Positive Action, GSK's program of HIV education, care, and community support, has been ongoing since 1992
- GSK's France Foundation has supported 31 programs in 12 African countries focusing on HIV prevention, education training, and healthcare in developing countries
- GSK funds community-led initiatives in more than 100 countries around the world
Innovative partnerships
- GSK has extended voluntary licenses to several companies to produce GSK antiretrovirals for sale and use in developing countries